Consumer Goods - Germany



Buy (old: Buy) 08.05.2024

**EUR 18.00** (old: EUR 18.00)

### Healthy Q1 results // FY24 guidance confirmed

Healthy Q1 results underpin that Westwing was able to continue the trend of yoy GMV growth witnessed in recent quarters. Q1 sales increased by 6% yoy to € 109m (eNuW: € 107.7m), showing an acceleration of growth versus Q4 (+2% yoy), driven by growth in active customers (+2% yoy to 1.28m) and basket size (+9% yoy to € 185). International and DACH grew 3% and 8% yoy, respectively, implying continued market share gains amid ongoing challenges in the German online Home & Living market (-4% yoy).


At the same time, efficiency measures are bearing fruit. Adj. EBITDA arrived in line with expectations at € 6m in Q1 (eNuW: € 6.5m), representing a margin improvement of 0.8ppts yoy to 5.8%. This was carried by a strong contribution margin expansion of +4ppts yoy to 32%, a favorable product mix (i.e. higher private label share, +5ppts yoy to 51% of GMV in Q1), reduced fulfilment expenses (-2ppts yoy) as well as lower G&A costs (-1ppts yoy) as a result of cost savings (i.e. consolidation of logistics and warehouses and streamlining the organization). Notably, Westwing was able to translate the favorable adj. EBITDA development into healthy FCF of € 4m in Q1, supported by net working capital of € -18m, likely concluding the reduction of excess inventory built up during Covid.

Westwing confirmed its FY24 guidance and with sales expected to develop within a range of -3% to 4% yoy to € 415-445m (eNuW: € 442m). While the Q1 performance was overall satisfactory, management continues to expect H2'24 sales to be weighed down by a strategic adjustment of the product offering in Spain and Italy (low to mid single-digit percentage impact) along with ongoing challenges in the home & living market as consumers continue to hold back on higher-value products such as furniture. The adj. EBITDA outlook was reiterated at € 14m to € 24m implying a 3.1 to 5.8% margin (eNuW: € 23.7m with a 5.4% margin). Considering € 6m adj. EBITDA in Q1, the bottom-line guidance looks achievable, in our view, while FCF for the full year should likely be close to break-even (eNuW: € 0.3m) due to one-off restructuring costs (i.e. complexity reduction, SaaS transition) and normalizing inventory patterns.


Overall, Westwing has adapted successfully to the current transition period towards a leaner and more scalable organizational setup. While visibility on a return of consumer confidence remains low, Westwing's mid-term prospects continue to look bright driven by the structural shift towards e-commerce and its unique positioning in the European home & living market. We reiterate our BUY recommendation

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	522.5	430.8	428.7	441.6	472.5	519.7
Sales growth	20.7%	-17.6%	-0.5%	3.0%	7.0%	10.0%
Adj. EBITDA	40.4	-4.2	17.8	23.7	30.3	38.9
Net debt (if net cash=0)	-87.1	-56.2	-82.0	-65.5	-70.9	-84.9
FCF	3.8	-21.4	29.5	0.3	15.5	24.1
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	0.55	-1.51	-0.61	-0.52	0.06	0.36
Adj. EBITDA margin	7.7%	-1.0%	4.2%	5.4%	6.4%	7.5%
ROCE	22.2%	-23.5%	-8.4%	-9.8%	7.0%	17.1%
EV/sales	1.4	0.3	0.2	0.2	0.2	0.2
EV/EBITDA	17.9	-14.2	9.0	7.3	4.5	2.9
PER	67.5	-5.8	-14.4	-16.9	144.8	24.6
Adjusted FCF yield	3.0%	-17.2%	4.2%	2.9%	14.7%	22.7%

Source: Company data, NuWays, Close price as of 22.04.2024



#### 150.0m 0.0m 2021 2022 2023 2024e 2025e Source: NuWays Research



#### 24.0% 12.0% 0.0% -12.0% -24.0% 2021 2022 2023 2024e 2025e 2026e

### **Company description**

Sales (2021-26e)

600.0m

450.0m

300.0m

Westwing is a leading e-commerce platform that allows customers to have the combined advantages of online and offline shops for home and living products. The company's product portfolio is complemented by consultation services from professional designers.

### **Share Performance** 10.00 9.60 9.20 8.80 8.40 8.00 7.60 7.20 6.80

07/23

High/low 52 weeks (€)	10.12 / 7.06
3m rel. performance	-4.9%
6m rel. performance	-18.4%
12m rel. performance	6.3%

11/23

#### Market data

Share price (in €)	8.00
Market cap (in € m)	175.7
Number of shares (in m pcs)	20.1
Enterprise value (in € m)	102.4
Ø trading volume (6 months)	7,200

#### Identifier

Bloomberg	WEW GR
Reuters	WEW
WKN	A2N4H0
ISIN	DE000A2N4H07

### Key shareholders

Zerena	28.9%
Amiral Gestion	9.9%
The Capital Group	7.6%
Blackwell Partners	5.7%
Bram Cornelisse	5.3%
Free Float	13.3%

### Fetimates changes

	Loumatoo	onangoe	•
	<u>2024e</u>	<u>2025e</u>	<u>2026e</u>
Sales	0%	0%	0%
EBIT	0%	0%	0%
EPS	-6%	6%	6%

### Comment on changes

Adjustments reflect lower share count due to buybacks implemented by the company

### Guidance

Source: NuWays Research

ROCE (2021-26e)

- Sales: -3% to +4% yoy
- Adj. EBITDA: € 14-24m

Preview / Review - 08.05.2024



with a **PT of € 18.00**, based on DCF, and keep the stock on our Alpha List.

Preview / Review - 08.05.2024



## **Financials**

Drafit and Ioon (EUD m)	2024	2022	2022	20246	20250	20260
Profit and loss (EUR m)	2021 522.5	2022 430.8	2023 428.7	2024e 441.6	2025e	2026e 519.7
Sales Sales growth	20.7%	-17.6%	-0.5%	3.0%	<b>472.5</b> 7.0%	10.0%
Cost of sales	265.7	228.1	-0.5% 215.7	216.9	230.2	251.6
Gross profit	256.8	202.7	213.7 213.0	210.9 <b>224.7</b>	242.3	268.1
Sales and marketing	156.4	134.8	135.8	135.5	143.5	157.4
General and administration	79.3	92.9	85.3	91.8	90.2	94.1
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	3.9	2.8	5.9	3.1	2.8	3.1
Other operating expenses	3.8	5.2	6.2	9.3	5.7	5.2
EBITDA	40.4	-9.4	11.4	14.0	23.7	31.6
Unusual or infrequent items	6.2	0.0	6.4	9.7	6.6	7.3
Adj. EBITDA	40.4	-4.2	17.8	23.7	30.3	38.9
Depreciation	9.2	12.2	13.2	15.2	10.8	9.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.8	5.8	6.6	7.6	7.2	7.6
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	27.4	-27.4	-8.4	-8.8	5.7	14.6
Interest income	0.0	0.0	1.1	0.0	0.0	0.0
Interest expenses	1.6	2.0	1.9	1.8	3.3	3.6
Investment income	-0.6	-0.9	0.1	0.0	-0.9	-1.0
Financial result	-2.2	-2.9	-0.7	-1.8	-4.3	-4.7
Recurring pretax income from continuing operations	25.2	-30.3	-9.1	-10.6	1.5	9.9
Extraordinary income/loss	-6.2	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	19.0	-30.3	-9.1	-10.6	1.5	9.9
Income tax expense	7.0	2.1	3.3	0.0	0.4	3.0
Net income from continuing operations	12.0	-32.4	-12.4	-10.6	1.0	7.0
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	12.0	-32.4	-12.4	-10.6	1.0	7.0
Minority interest	0.0	0.0	-0.2	-0.2	-0.2	-0.2
Net profit (reported)	12.0	-32.4	-12.2	-10.4	1.2	7.2
Average number of shares	21.7	21.5	20.1	20.1	20.1	20.1
EPS reported	0.55	-1.51	-0.61	-0.52	0.06	0.36
Duefit and lose (semmen size)	2024	2022	2022	20246	20250	20260
	2021	2022	2023	2024e	2025e	2026e
Profit and loss (common size)  Sales Cost of sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales Cost of sales	<b>100.0%</b> 50.9%	<b>100.0%</b> 52.9%	<b>100.0%</b> 50.3%	<b>100.0%</b> 49.1%	<b>100.0%</b> 48.7%	<b>100.0%</b> 48.4%
Sales Cost of sales Gross profit	<b>100.0%</b> 50.9% <b>49.1%</b>	100.0% 52.9% 47.1%	<b>100.0%</b> 50.3% <b>49.7%</b>	<b>100.0%</b> 49.1% <b>50.9%</b>	100.0% 48.7% 51.3%	100.0% 48.4% 51.6%
Sales Cost of sales Gross profit Sales and marketing	<b>100.0%</b> 50.9% <b>49.1%</b> 29.9%	<b>100.0%</b> 52.9% <b>47.1%</b> 31.3%	<b>100.0%</b> 50.3% <b>49.7%</b> 31.7%	<b>100.0%</b> 49.1% <b>50.9%</b> 30.7%	<b>100.0%</b> 48.7% <b>51.3%</b> 30.4%	100.0% 48.4% 51.6% 30.3%
Sales Cost of sales Gross profit Sales and marketing General and administration	100.0% 50.9% 49.1% 29.9% 15.2%	100.0% 52.9% 47.1% 31.3% 21.6%	100.0% 50.3% 49.7% 31.7% 19.9%	100.0% 49.1% 50.9% 30.7% 20.8%	100.0% 48.7% 51.3% 30.4% 19.1%	<b>100.0%</b> 48.4% <b>51.6%</b> 30.3% 18.1%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	100.0% 50.9% 49.1% 29.9% 15.2% 0.0%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 0.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 0.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 2.7% 1.5% 4.2%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 2.2% 5.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 7.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 2.2% 5.4% 3.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 0.0% 1.7%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8% 0.0% 1.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.7%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 0.0% 1.7% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8% 0.0% 1.5% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 1.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8% 0.0% 1.5% 0.0% 2.8%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 1.2% 0.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 1.8% 0.0% 1.5% 0.0% 2.8% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 1.2% 0.0% 0.7%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 0.0% 0.7%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 1.5% 0.0% 0.7% -0.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 0.0% 0.7% -0.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg.	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg.	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg.	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg.	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 1.5% 0.0% 0.7% -0.2% neg.	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 0.6% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 2.8% 0.0% 0.7% -0.2% neg.
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg2.1%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 2.8% 0.0% 0.7% -0.2% neg. 1.9%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg2.1% 0.0%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 2.8% 0.0% 0.7% -0.2% neg. 1.9% 0.0%
Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0% 0.3%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 1.5% 0.0% 2.8% 0.0% 0.7% -0.2% neg. 1.9% 0.0% 1.9%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4% 0.0% -2.4% 0.0%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0% 0.3% 30.0%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 0.0% 0.7% -0.2% neg. 1.9% 0.0% 1.9% 30.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0% -6.9% -7.5%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4% 0.0% -2.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0% 0.3% 30.0% 0.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 0.0% 0.7% -0.2% neg. 1.9% 0.0% 1.9% 30.0% 1.3%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income Income from continuing operations Net income	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% -6.9% -7.5%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9% -2.9%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4% 0.0% -2.4% -2.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0% 0.3% 30.0% 0.2% 0.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 0.0% 0.7% -0.2% neg. 1.9% 0.0% 1.9% 30.0% 1.3%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3%	100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0% -6.9% -7.5%	100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9%	100.0% 49.1% 50.9% 30.7% 20.8% 0.0% 0.7% 2.1% 3.2% 5.4% 3.4% 0.0% 1.7% 0.0% -2.0% 0.0% 0.4% 0.0% neg2.4% 0.0% -2.4%	100.0% 48.7% 51.3% 30.4% 19.1% 0.0% 0.6% 1.2% 5.0% 1.4% 6.4% 2.3% 0.0% 1.5% 0.0% 0.7% -0.2% neg. 0.3% 0.0% 0.3% 30.0% 0.2%	100.0% 48.4% 51.6% 30.3% 18.1% 0.0% 1.0% 6.1% 1.4% 7.5% 0.0% 0.0% 0.7% -0.2% neg. 1.9% 0.0% 1.9% 30.0% 1.3%

Source: Company data, NuWays

Preview / Review - 08.05.2024



Balance sheet (EUR m) Intangible assets Property, plant and equipment Financial assets FIXED ASSETS Inventories Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY MINORITY INTEREST	2021 18.9 55.5 0.0 74.4 54.9 11.5 18.9 97.4 8.2 12.1 203.0 277.4	2022 23.3 53.2 2.3 78.8 45.2 12.6 22.2 62.3 3.6 3.6 149.5 228.3	2023 19.3 44.6 1.6 65.5 28.1 12.1 21.2 81.4 1.5 7.1 151.4 216.9	2024e 21.0 33.8 1.6 56.4 27.5 12.5 21.2 71.5 1.5 7.1 141.3 197.7	2025e 21.0 33.8 1.6 56.4 28.5 13.3 21.2 76.9 1.5 7.1 148.5 204.9	2026e 21.0 33.8 1.6 56.4 30.4 14.7 21.2 90.9 1.5 7.1 165.8 222.2
Property, plant and equipment Financial assets FIXED ASSETS Inventories Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	0.0 74.4 54.9 11.5 18.9 97.4 8.2 12.1 203.0 277.4	2.3 78.8 45.2 12.6 22.2 62.3 3.6 3.6 149.5 228.3	1.6 <b>65.5</b> 28.1 12.1 21.2 81.4 1.5 7.1 <b>151.4</b> <b>216.9</b>	1.6 <b>56.4</b> 27.5 12.5 21.2 71.5 1.5 7.1 <b>141.3</b>	1.6 <b>56.4</b> 28.5 13.3 21.2 76.9 1.5 7.1 <b>148.5</b>	1.6 56.4 30.4 14.7 21.2 90.9 1.5 7.1 165.8
Financial assets  FIXED ASSETS Inventories Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	0.0 74.4 54.9 11.5 18.9 97.4 8.2 12.1 203.0 277.4	2.3 78.8 45.2 12.6 22.2 62.3 3.6 3.6 149.5 228.3	1.6 <b>65.5</b> 28.1 12.1 21.2 81.4 1.5 7.1 <b>151.4</b> <b>216.9</b>	1.6 <b>56.4</b> 27.5 12.5 21.2 71.5 1.5 7.1 <b>141.3</b>	1.6 <b>56.4</b> 28.5 13.3 21.2 76.9 1.5 7.1 <b>148.5</b>	1.6 56.4 30.4 14.7 21.2 90.9 1.5 7.1 165.8
Inventories Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	74.4 54.9 11.5 18.9 97.4 8.2 12.1 203.0 277.4	78.8 45.2 12.6 22.2 62.3 3.6 3.6 149.5 228.3	65.5 28.1 12.1 21.2 81.4 1.5 7.1 151.4 216.9	56.4 27.5 12.5 21.2 71.5 1.5 7.1 141.3	56.4 28.5 13.3 21.2 76.9 1.5 7.1 148.5	56.4 30.4 14.7 21.2 90.9 1.5 7.1 165.8
Inventories Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	54.9 11.5 18.9 97.4 8.2 12.1 203.0 277.4	45.2 12.6 22.2 62.3 3.6 3.6 149.5 228.3	28.1 12.1 21.2 81.4 1.5 7.1 <b>151.4</b> 216.9	27.5 12.5 21.2 71.5 1.5 7.1 <b>141.3</b>	28.5 13.3 21.2 76.9 1.5 7.1 148.5	30.4 14.7 21.2 90.9 1.5 7.1 <b>165.8</b>
Accounts receivable Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	11.5 18.9 97.4 8.2 12.1 <b>203.0</b> <b>277.4</b>	12.6 22.2 62.3 3.6 3.6 149.5 228.3	12.1 21.2 81.4 1.5 7.1 <b>151.4</b> <b>216.9</b>	12.5 21.2 71.5 1.5 7.1 <b>141.3</b>	13.3 21.2 76.9 1.5 7.1 <b>148.5</b>	14.7 21.2 90.9 1.5 7.1 <b>165.8</b>
Other assets and short-term financial assets Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	18.9 97.4 8.2 12.1 203.0 277.4	22.2 62.3 3.6 3.6 149.5 228.3	21.2 81.4 1.5 7.1 <b>151.4</b> <b>216.9</b>	21.2 71.5 1.5 7.1 <b>141.3</b>	21.2 76.9 1.5 7.1 <b>148.5</b>	21.2 90.9 1.5 7.1 <b>165.8</b>
Liquid assets Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	97.4 8.2 12.1 <b>203.0</b> <b>277.4</b>	62.3 3.6 3.6 <b>149.5</b> <b>228.3</b>	81.4 1.5 7.1 <b>151.4</b> <b>216.9</b>	71.5 1.5 7.1 <b>141.3</b>	76.9 1.5 7.1 <b>148.5</b>	90.9 1.5 7.1 <b>165.8</b>
Deferred taxes Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	8.2 12.1 203.0 277.4 119.3	3.6 3.6 <b>149.5</b> <b>228.3</b>	1.5 7.1 <b>151.4</b> <b>216.9</b>	1.5 7.1 <b>141.3</b>	1.5 7.1 <b>148.5</b>	1.5 7.1 <b>165.8</b>
Deferred charges and prepaid expenses CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	12.1 203.0 277.4 119.3	3.6 <b>149.5</b> <b>228.3</b>	7.1 <b>151.4</b> <b>216.9</b>	7.1 <b>141.3</b>	7.1 <b>148.5</b>	7.1 <b>165.8</b>
CURRENT ASSETS TOTAL ASSETS SHAREHOLDERS EQUITY	203.0 277.4 119.3	149.5 228.3	151.4 216.9	141.3	148.5	165.8
SHAREHOLDERS EQUITY	277.4 119.3	228.3	216.9			
		90.0				
			88.5	69.1	74.1	75.3
	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	1.1	2.1	2.1	2.1	2.1	2.1
Other provisions and accrued liabilities	0.7	0.6	1.5	1.5	1.5	1.5
Short-term liabilities to banks	0.7	0.0	0.0	0.0	0.0	0.0
	56.8	34.1	35.9	36.1	38.3	41.9
Accounts payable Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	83.1	91.4	78.9	78.9	78.9	91.4
Deferred taxes	5.1	2.3	3.1	3.1	3.1	3.1
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	139.9	125.5	114.8	115.0	117.2	133.3
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	277.4	228.3	216.9	197.7	204.9	222.2
	_,,,,	220.0	210.0	10111	20 110	
Balance sheet (common size)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	6.8%	10.2%	8.9%	10.6%	10.2%	9.4%
Property, plant and equipment	20.0%	23.3%	20.6%	17.1%	16.5%	15.2%
Financial assets	0.0%	1.0%	0.7%	0.8%	0.8%	0.7%
FIXED ASSETS	26.8%	34.5%	30.2%	28.5%	27.5%	25.4%
Inventories	19.8%	19.8%	13.0%	13.9%	13.9%	13.7%
Accounts receivable	4.1%	5.5%	5.6%	6.3%	6.5%	6.6%
Other assets and short-term financial assets	6.8%	9.7%	9.8%	10.7%	10.3%	9.5%
Liquid assets	35.1%	27.3%	37.5%	36.2%	37.5%	40.9%
Deferred taxes	3.0%	1.6%	0.7%	0.8%	0.7%	0.7%
Deferred charges and prepaid expenses	4.4%	1.6%	3.3%	3.6%	3.5%	3.2%
CURRENT ASSETS	73.2%	65.5%	69.8%	71.5%	72.5%	74.6%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	43.0%	39.4%	40.8%	35.0%	36.2%	33.9%
MINORITY INTEREST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	0.4%	0.9%	1.0%	1.1%	1.0%	0.9%
Other provisions and accrued liabilities	0.3%	0.3%	0.7%	0.8%	0.7%	0.7%
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	20.5%	14.9%	16.6%	18.3%	18.7%	18.8%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other liabilities (incl. from lease and rental contracts)	30.0%	40.0%	36.4%	39.9%	38.5%	41.1%
Deferred taxes	1.8%	1.0%	1.4%	1.6%	1.5%	1.4%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	50.4%	55.0%	52.9%	58.2%	57.2%	60.0%
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Preview / Review - 08.05.2024



Cash flow statement (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net profit/loss	12.0	-32.4	-12.4	-10.6	1.0	7.0
Depreciation of fixed assets (incl. leases)	9.2	12.2	13.2	15.2	10.8	9.4
Amortisation of goodwill & intangible assets	3.8	5.8	6.6	7.6	7.2	7.6
Other costs affecting income / expenses	-2.6	20.0	6.5	1.3	6.0	10.0
Cash flow from operating activities	6.8	-18.6	29.0	3.0	17.5	26.2
Increase/decrease in inventory	-24.7	9.7	17.1	0.6	-1.0	-1.9
Increase/decrease in accounts receivable	5.9	-1.1	0.5	-0.4	-0.9	-1.3
Increase/decrease in accounts payable	15.1	-22.7	1.8	0.2	2.2	3.6
Increase/decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in working capital	-3.7	-14.1	19.4	0.4	0.4	0.3
Cash flow from operating activities	18.7	-7.5	33.3	13.9	25.4	34.3
CAPEX	14.9	13.9	5.4	13.7	9.9	10.1
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	1.1	2.5	1.6	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-16.0	-11.4	-3.8	-13.7	-9.9	-10.1
Cash flow before financing	2.7	-23.9	26.3	0.3	15.5	24.1
Increase/decrease in debt position	0.0	-4.2	-0.1	0.0	0.0	0.0
Purchase of own shares	0.0	-0.5	-3.7	0.0	0.0	0.0
Capital measures	0.4	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-10.1	1.0	-20.1	-10.1	-10.1	-10.1
Effects of exchange rate changes on cash	-0.5	0.1	-0.1	0.0	0.0	0.0
Cash flow from financing activities	-9.7	-2.7	-23.9	-10.1	-10.1	-10.1
Increase/decrease in liquid assets	-7.5	-26.5	9.7	-9.9	5.4	14.0
Liquid assets at end of period	97.4	75.9	81.4	71.5	76.9	90.9
Key ratios (EUR m)	2021	2022	2023	2024e	2025e	2026e
P&L growth analysis						
Sales growth	20.7%	-17.6%	-0.5%	3.0%	7.0%	10.0%
EBITDA growth	-19.2%	-123.3%	-221.3%	22.9%	69.2%	33.3%
EBIT growth	-30.4%	-200.0%	-69.3%	4.6%	-165.1%	155.4%
EPS growth	-53.2%	-373.1%	-59.7%	-15.2%	-111.7%	489.8%
Efficiency						
Sales per employee	290.1	253.4	218.4	264.2	287.7	264.8
EBITDA per employee	22.4	-5.5	5.8	8.4	14.4	16.1
No. employees (average)	1,801	1,700	1,963	1,672	1,642	1,963
Balance sheet analysis			/			
Avg. working capital / sales	1.5%	3.9%	3.3%	0.9%	0.8%	0.6%
Inventory turnover (sales/inventory)	4.8	5.0	7.7	7.9	8.1	8.3
Accounts receivable turnover	8.0	10.7	10.3	10.3	10.3	10.3
Accounts payable turnover	78.0	54.6	60.7	60.7	60.7	60.7
Cash flow analysis	0.0	04.4	00.5	0.0	45.5	04.4
Free cash flow	3.8	-21.4	29.5	0.3	15.5	24.1
Free cash flow/sales	0.7%	-5.0%	6.9%	0.1%	3.3%	4.6% 347.4%
FCF / net profit	31.7%	66.0%	neg.	neg.	1507.2%	
Capex / sales Solvency	3.1%	3.8%	1.6%	3.1%	2.1%	1.9%
Net debt	-87.1	-56.2	-82.0	-65.5	-70.9	04.0
Net Debt/EBITDA	0.0	0.0	-62.0 0.0	0.0	0.0	-84.9 0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	21.6%	24.4%	31.4%	29.4%	55.1%	60.6%
Returns	21.070	24.470	31.470	23.470	33.170	00.070
ROCE	22.2%	-23.5%	-8.4%	-9.8%	7.0%	17.1%
ROE	10.1%	-36.0%	-13.8%	-9.0 % -15.0%	1.6%	9.5%
Adjusted FCF yield	3.0%	-17.2%	4.2%	2.9%	14.7%	22.7%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0 %	0.0	0.070	0.0	0.0
EPS reported	0.55	-1.51	-0.61	-0.52	0.06	0.36
Average number of shares	21.7	21.5	20.1	20.1	20.1	20.1
Valuation ratios	21.1	21.0	20.1	20.1	۷. ۱	۷.۱
		2.1	2.0	2.5	2.4	2.3
	6.8					
P/BV	6.8 1.4					0.2
P/BV EV/sales	1.4	0.3	0.2	0.2	0.2	
P/BV						0.2 2.9 6.4

Preview / Review - 08.05.2024



### **Disclosures**

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

#### Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
Westwing Group SE	2

Historical target price and	rating changes for Westwing	Group SE			
Company	Date	Analyst	Rating	Target Price	Close
Westwing Group SE	01.04.2024	Schüssler, Mark	Buy	EUR 18.00	EUR 7.90
	28.03.2024	Schüssler, Mark	Buy	EUR 17.00	EUR 7.69
	09.11.2023	Salis, Christian	Buy	EUR 19.00	EUR 8.38
	10.08.2023	Salis, Christian	Buy	EUR 18.00	EUR 8.33
	12.05.2023	Salis, Christian	Buy	EUR 17.00	EUR 8.32

Preview / Review - 08.05.2024



### 1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

### 2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

### 3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

### 4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

### 5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

### 6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

### 7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

### 8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: <a href="https://www.nuways-ag.com">www.nuways-ag.com</a>

Date of publication creation: 08/05/2024 07:31 AM

Date of publication dissemination: 08/05/2024 07:31 AM

Preview / Review - 08.05.2024



### **Contacts**

### **NuWays AG**

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



**Philipp Sennewald** 

Analyst

philipp.sennewald@nuways-ag.com



**Henry Wendisch** 

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/>
≥



<u>LinkedIn</u>



8